top
Search terms
Results 1 - 4 of 4 - ordered by :
Ehjcvp

Vice versa, patients presenting with acute coronary syndromes (ACS) develop AF in 621% of cases, hence, through the presence of vascular disease, these patients automatically require anticoagulation ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Miklos Rohla, Thomas W. Weiss, Johann Wojta, Alexander Niessner, Kurt Huber

Date : 01/07/2015 Item size : 293945 bytes
Ehjcvp

The aim of this review is to provide an overview of the evidence from randomized, clinical trials and epidemiological studies, with a focus on the optimal duration of dual antiplatelet therapy (DAPT) ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Pierre Sabouret, Sophie K. Rushton-Smith, Mathieu Kerneis, Johanne Silvain, Jean-Philippe Collet, Gilles Montalescot

Date : 01/07/2015
Ehjcvp

Due to the introduction of foreign materials to the circulation (either temporarily or permanently) and due to a certain damage to the endothelium or endocardium, the risk of thrombotic complications ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, P. Widimský, V. Kočka, F. Roháč, P. Osmančík

Date : 01/04/2016
Ehjcvp

Abstract Aims Clinical utilization of dual antiplatelet therapy (DAPT) in patients with renal impairment (RI) following percutaneous coronary interventions (PCI) represents an urgent, unmet need ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Long Zhe Guo, Moo Hyun Kim, Chang Heon Shim, Sun Young Choi, Victor L. Serebruany

Date : 01/07/2016